UMIFENOVIR

Umifenovir is a broad antiviral inhibiting membrane fusion used for influenza and respiratory infections. Side effects include GI upset, headache, allergic reactions, and mild liver enzyme elevations. Only GMP materials will be supplied, logistics all according to GDP.

Product Description


Mechanism of Action

UMIFENOVIR exhibits a high-dimensional biochemical activity profile integrating catalyticdomain modulation, multiaxis signalling disruption, mitochondrialnetwork recalibration, ionflux redistribution, redoxstate restructuring, cytoskeletal remodelling, membraneelectrochemical modulation and transcriptionfactor pathway reprogramming. Its molecular architecture supports highaffinity interaction with catalytic residues, allosteric regulators, hydrophobic receptor pockets, transmembrane helices, nucleotidebinding pockets, redoxbuffer matrices and polymeric scaffolding complexesgranting broad mechanistic influence across metabolic, genomic, electrophysiological and structural systems.

UMIFENOVIR may reorganise phosphorylationflow geometry across ERK/MAPK/JNK/p38 cascades, alter PI3KAKT survival signalling, shift Gprotein coupling patterns, redistribute Ca²⁺ microdomains, reshape IP/DAG signalling topology, and recalibrate cAMPPKA amplitude dynamics. Mitochondrial impacts include ETCcomplex activation shifts, ATP/ADP turnover modulation, ROSthreshold displacement, mitochondrialmembrane potential polarity changes and ERmitochondrial stresssignal coupling, making the compound highly valuable for mechanistic and translational research models.

Advanced

  • Kinomescale catalyticcascade mapping and interference modelling
  • Ultraresolution ligand docking and conformationaltransition analysis
  • UPR/ERstress, mitophagy, autophagy and oxidativestress crossnetwork characterisation
  • Multiomics system reconstruction (RNAseq, metabolomics, proteomics, phosphoproteomics)
  • Cytoskeletal mechanics and polymerturnover modelling
  • Cellfate mapping across apoptosis, necroptosis, ferroptosis, pyroptosis and parthanatos
  • Machinelearning driven SAR/QSAR molecularperformance prediction

Toxicodynamics & Cellular Hazard Spectrum

  • ROS hyperaccumulation and antioxidant-system collapse
  • Mitochondrial fragmentation, ETC shutdown or hyperleak states
  • Severe Na⁺/K⁺/Ca²⁺ ionic-flux dysregulation
  • Cytoskeletal depolymerisation and membrane-integrity failure
  • NF-κB, STAT and IRF inflammatoryaxis hyperactivation
  • Engagement of multiaxis programmed-cell-death pathways
  • Epigenetic drift including methylation and acetylation imbalance

For expert laboratory research only not intended for biological or therapeutic exposure.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C22H25BrN2O3S

Molecular Weight

477.4 g/mol

CAS Number

131707-25-0

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

"Expected to be poorly soluble"

Purity

Purity information is available upon request (COA).

Synonym

umifenovir; 131707-25-0; ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)indole-3-carboxylate; 93M09WW4RU; 1H-Indole-3-carboxylic acid, 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-[(phenylthio)methyl]-, ethyl ester

IUPAC/Chemical Name

ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)indole-3-carboxylate

InChl Key

KCFYEAOKVJSACF-UHFFFAOYSA-N

InChl Code

InChI=1S/C22H25BrN2O3S/c1-5-28-22(27)20-18(13-29-14-9-7-6-8-10-14)25(4)17-11-16(23)21(26)15(19(17)20)12-24(2)3/h6-11,26H,5,12-13H2,1-4H3

References

https://pubchem.ncbi.nlm.nih.gov/compound/131411;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download